AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Akebia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.68+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $183.36M
- P/E (TTM)
- –
- Dividend yield
- –
Akebia Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Market Cap | $188.46M | $197.05M |
| Enterprise Value | $82.48M | $106.56M |
| PS Ratio | 0.86 | 3.93 |
| PB Ratio | 7.53 | 2.14 |
| P/FCF Ratio | 4.68 | 18.25 |
| P/OCF Ratio | 4.54 | 13.78 |
Enterprise value
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.38 | 2.69 |
| EV / FCF | 2.05 | 21.02 |
Income (trailing twelve months)
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Revenue | $219.06M | $57.94M |
| Gross Profit | $174.43M | $90.47M |
| Operating Income | -$15.13M | -$21.44M |
| Pretax Income | -$27.85M | -$14.45M |
| Net Income | -$29.67M | -$22.46M |
| EBITDA | -$15.13M | -$16.91M |
| EPS (Diluted) | -$0.11 | -$0.83 |
Margins
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 79.6% | 52.3% |
| Operating Margin | -6.90% | -44.5% |
| Pretax Margin | -12.7% | -13.0% |
| Profit Margin | -13.5% | -39.2% |
| EBITDA Margin | -6.90% | -31.3% |
| FCF Margin | 18.4% | -8.85% |
Returns
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -109.4% | -53.1% |
| Return on Assets (ROA) | -8.53% | -41.0% |
| Return on Capital Employed (ROCE) | -8.01% | -37.8% |
Growth
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 7.52% | 6.01% |
| Revenue Growth (3Y CAGR) | -6.88% | 2.25% |
| Revenue Growth (5Y CAGR) | -4.33% | 6.42% |
Balance sheet
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $155.55M | $62.42M |
| Total Debt | $49.56M | $120.13M |
| Net Cash (Debt) | $105.99M | $15.68M |
| Net Cash Per Share | $0.38 | $0.65 |
| Equity (Book Value) | $25.02M | $48.79M |
| Book Value Per Share | $0.09 | $1.36 |
| Tangible Book Value | -$34.03M | $23.06M |
| Working Capital | $68.69M | $75.77M |
Financial position
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.43 | 3.30 |
| Quick Ratio | 1.30 | 2.39 |
| Debt / Equity | 1.98 | 0.51 |
| Debt / FCF | 1.23 | 5.05 |
Cash flow (trailing twelve months)
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $41.55M | -$12.35M |
| Capital Expenditures | -$1.29M | -$1.06M |
| Free Cash Flow | $40.26M | -$20.28M |
| FCF Per Share | $0.15 | -$0.41 |
Efficiency
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.63 | 0.38 |
| Inventory Turnover | 3.00 | 2.67 |
| Revenue Per Employee | $1.13M | $398.96K |
| Profits Per Employee | -$152.92K | -$732.08K |
| Employee Count | 194 | 73 |
Dividends and yields
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -15.7% | -21.2% |
| FCF Yield | 21.4% | -7.64% |
Shares
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 277,106,000 | 59,128,900 |
| Shares Change (YoY) | 11.7% | 11.1% |
| Shares Change (QoQ) | 1.43% | 0.54% |
| Float | 268,937,000 | 48,744,500 |
| Shares Held by Insiders | 2.95% | 11.8% |
| Shares Held by Institutions | 39.7% | 59.4% |
Taxes
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Income Tax | $1.82M | $91.50K |
Scores
| Measure | Akebia Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -5.75 | 0.10 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Akebia Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.